» Articles » PMID: 16288213

K-ras Activation Generates an Inflammatory Response in Lung Tumors

Overview
Journal Oncogene
Date 2005 Nov 17
PMID 16288213
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Activating mutations in K-ras are one of the most common genetic alterations in human lung cancer. To dissect the role of K-ras activation in bronchial epithelial cells during lung tumorigenesis, we created a model of lung adenocarcinoma by generating a conditional mutant mouse with both Clara cell secretory protein (CC10)-Cre recombinase and the Lox-Stop-Lox K-ras(G12D) alleles. The activation of K-ras mutant allele in CC10 positive cells resulted in a progressive phenotype characterized by cellular atypia, adenoma and ultimately adenocarcinoma. Surprisingly, K-ras activation in the bronchiolar epithelium is associated with a robust inflammatory response characterized by an abundant infiltration of alveolar macrophages and neutrophils. These mice displayed early mortality in the setting of this pulmonary inflammatory response with a median survival of 8 weeks. Bronchoalveolar lavage fluid from these mutant mice contained the MIP-2, KC, MCP-1 and LIX chemokines that increased significantly with age. Cell lines derived from these tumors directly produced MIP-2, LIX and KC. This model demonstrates that K-ras activation in the lung induces the elaboration of inflammatory chemokines and provides an excellent means to further study the complex interactions between inflammatory cells, chemokines and tumor progression.

Citing Articles

Neutrophil Engulfment in Cancer: Friend or Foe?.

Lu T, Li W Cancers (Basel). 2025; 17(3).

PMID: 39941753 PMC: 11816126. DOI: 10.3390/cancers17030384.


Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.

He D, Bai R, Chen N, Cui J Chin J Cancer Res. 2024; 36(4):421-441.

PMID: 39246706 PMC: 11377883. DOI: 10.21147/j.issn.1000-9604.2024.04.06.


MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.


CXCR1/2 antagonism inhibits neutrophil function and not recruitment in cancer.

Kwak J, Nguyen H, Camai A, Huffman G, Mekvanich S, Kenney N Oncoimmunology. 2024; 13(1):2384674.

PMID: 39076249 PMC: 11285219. DOI: 10.1080/2162402X.2024.2384674.


Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma.

Yang M, Shulkin N, Gonzalez E, Castillo J, Yan C, Zhang K bioRxiv. 2024; .

PMID: 38948812 PMC: 11213232. DOI: 10.1101/2024.06.19.599651.